Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
168.4 USD | +1.51% | +5.78% | -14.65% |
May. 06 | BNP Paribas Exane Adjusts Price Target on Zoetis to $232 From $237 | MT |
May. 06 | The market resurrects the Fed Put |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.76 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.65% | 76.86B | B+ | ||
-9.26% | 6.66B | B- | ||
+27.25% | 3.78B | B- | ||
-2.92% | 3.14B | B- | ||
+13.18% | 1.59B | - | ||
-14.30% | 1.43B | B | ||
-23.61% | 1.28B | C- | ||
-9.13% | 1.2B | - | ||
-6.84% | 1.22B | - | ||
+3.84% | 1.09B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ZTS Stock
- Ratings Zoetis Inc.